Novo Nordisk (NVO) has reportedly been criticized by the U.K.'s Prescription Medicines Code of Practice Authority, or PMCPA, for mischaracterizing certain payments to patients and healthcare groups.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback